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A rapid and sensitive spectrofluorimetric method was developed for the determination of amlodipine 
(AD), a calcium channel blocker, in the plasma. The type of solvent, the wavelength range, and the range 
of AD concentration were selected to optimize the experimental conditions. The calibration curves were 
linear (r2 ≥0.997) in the concentration range of 0.1-12.5 ppm of AD. The limit of quantitation and limit 
of detection values for the method for plasma samples were 0.1 ppm and 0.07 ppm, respectively. The 
precision calculated as the relative standard deviation was less than 3.5%, and the accuracy (relative 
error) was better than 5.5% (n=6). The method developed in this study can be directly and easily applied 
for the determination of AD in the plasma without derivatization in plasma.
Uniterms: Amlodipine/determination. Spectrofluorimetric method/validation. Human plasma.
Método espectrofluorometrico rápido e sensível é descrito para a determinação de anlodipina (AD), um 
bloqueador de canais de cálcio, em amostras de plasma. O tipo de solvente, a faixa de comprimento de 
onda e a faixa de concentração foram escolhidas a fim de otimizar as condições experimentais. As curvas 
de calibração foram lineares (r ≥ 0,997) na faixa de concentração de 0,1-12,5 ppm de AD. Os valores 
LoQ e LoD do método para amostras de plasma foram 0,1 ppm e 0,07 ppm, respectivamente. A precisão 
calculada como desvio padrão relativo (RSD) foi menor do que 3,5% e a precisão (erro relativo) foi 
melhor do que 5,5% (n=6). O método desenvolvido neste estudo pode ser fácil e diretamente aplicado 
para a determinação de AD sem derivatização no plasma.
Unitermos: Anlodipina/determinação. Método espectrofluorimétrico/validação. Plasma humano.
INTRODUCTION
Amlodipine (AD), 2-[(2-aminoethoxy)methyl]-4-(2-
-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-
-methyl-1,4-dihydropyridine (Figure 1), is a dihydro-
pyridine calcium channel blocker, which is used for the 
treatment of hypertension and angina (Reynolds, 1996; 
European Pharmacopoeia, 2001; Civantos, Aleixandre, 
2004). In addition, AD may be used for dilated cardiomy-
opathy, and AD has ameliorating effects on the plasma 
and myocardial catecholamines levels and significantly 
reduces calcium deposition (Resnick, Laragh, 1985; Khat-
tar et al., 1999).
Several analytical procedures are available for the 
FIGURE 1- Structural formula of AD.
analysis of AD in the plasma/serum, such as high-perfor-
mance liquid chromatography (HPLC) with fluorescence 
detection (Tatar, Atamaca, 2001; Bahrami, Mirzaeei, 
2004); ultraviolet (UV) detection (Yeung et al., 1991; 
Coseberg, Carson, 1997; Patel et al., 1998; Johansen, 
Genner, 2003; Zarghi et al., 2005); amperometric detec-
tion (Shirmooka et al., 1989; Josefsson et al., 1995); high-
performance thin layer chromatography method (Pandya 
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et al., 1995); liquid chromatography tandem mass spec-
trometry (LC-MS-MS) method (Yasud et al., 1996; Chen 
et al., 2001; Massaroti et al., 2005; Nirogi et al., 2006; Ma 
et al., 2007; Sirikatitham et al., 2008); gas chromatography 
(GC) method (Bresford et al., 1987; Scharpf et al., 1994; 
Monkman et al., 1996); GC-MS method (Feng et al., 1998) 
and electrochemical analysis (Gazy, 2004). Generally, AD 
in the plasma has been analyzed by HPLC (-MS) and GC 
methods. These methods have the required sensitivity 
and selectivity for the analysis of AD in biological flu-
ids. However the sophisticated instrumentation and high 
cost of analysis involved in these methods have limited 
their use in the laboratories for the analysis of AD in its 
biological samples. Moreover, these instruments are not 
available in most laboratories, particularly in third world 
countries. Typically, spectrofluorimetry is one of the most 
convenient analytical techniques, because of its inherent 
simplicity, low cost, and wide availability of the instru-
ment in most laboratories (Frei, Lawrence, 1981; Knap, 
1979; Belal et al., 2008; Shaalan, Belal, 2010). However, 
many of the analytical methods reported in the literature 
have limitations because these methods require derivatiza-
tion of AD using different substances. These methods have 
disadvantages such as poor selectivity, heating, or an ex-
traction step and are expensive and time-consuming (Frei, 
Lawrence, 1981; Abdel-Wadood et al., 2008; Belal et al., 
2008; Shaalan, Belal, 2010). A literature survey indicated 
3 spectrofluorimetric methods for the analysis of AD in 
pure and pharmaceutical dosage forms. The first method 
was based on a condensation reaction with ninhydrin and 
phenylacetaldehyde in a neutral buffered medium, and the 
second method was based on a reaction with 7-chloro-4-ni-
tro-2,1,3-benzoxadiazole (NBD-Cl) reagent in a slightly 
basic buffered medium (Abdel-Wadood et al., 2008); 
further, Shaalan and Belal (2010) examined simultane-
ous spectrofluorimetric determination of AD besylate and 
valsartan in tablets containing a combination of the drugs. 
In addition, the binding of aspirin and AD to human serum 
albumin in an aqueous solution at pH 7.4 has been exam-
ined using multiple techniques (fluorescence quenching, 
resonance light scattering, three-dimensional fluorescence 
spectroscopy, Fourier transform-infrared [FT-IR] spectros-
copy, and zeta-potential measurements) (Abdollahpour 
et al., 2011). Literature review indicates that to date no 
studies have reported concerning the spectrofluorimetric 
determination of AD in the plasma. This encouraged us to 
study the native fluorescence of the drug in an attempt to 
develop a simple and sensitive spectrofluorimetric method 
for determination of the drug without derivatization, either 
alone or in its co-formulated preparations with a simple 
sample preparation. The method was extended to the in 
vitro determination of the drug in spiked human samples, 
and we obtained promising results.
MATERIAL AND METHODS
Apparatus
The fluorescence spectra and measurements were 
recorded using a Perkin Elmer LS 45 fluorescence spec-
trometer equipped with FL WinLab software, and a 150 
W xenon arc lamp: the excitation (lexc) and emission (lem) 
wavelengths were 360 nm and 440 nm, respectively. Mea-
surements were performed using a 10-mm quartz cell. Slit 
width for both monochromators was set at 10 nm.
Reagents
AD used as a reference substance (purity 99.2%) 
was purchased from Novartis Pharmaceutical Industry 
(Ankara, Turkey). All analytical chemicals were purchased 
from Merck (Germany). Drug-free blank plasma was ob-
tained from 3 hospitals in Erzurum, Turkey.
Preparation of calibration standards and quality 
control samples
The standard stock solution of AD (100 ppm) was 
prepared by dissolving an appropriate amount of AD in 
ethanol. The stock solution was subsequently diluted in the 
same diluents to obtain working standard solutions (WS) at 
8 concentrations level. All solutions were stored at -4 ◦C.
A suitable amount of the WS of AD was added to 0.2 
mL of the drug free human plasma to yield final respective 
concentrations of 0.1, 1, 2, 4, 6, 8, 10 and 12.5 ppm of AD 
in the plasma. Quality control (QC) samples (1.5, 4.5, and 
7.5 ppm) were also prepared in a similar manner.
Sample preparation procedure
The plasma samples were stored at -20 oC and al-
lowed to thaw at room temperature before processing. 
An appropriate amount of standard solutions of AD were 
spiked into 0.2 mL of each concentration of drug-free 
human plasma and mixed. Then, 1.0 mL buffer solution 
(1M sodium carbonate [Na2CO3]/4 M sodium bicar-
bonate [NaHCO3], v/v) and 3 mL of extraction solvent 
(ether:hexane 1:1 v/v) were added, and the solution was 
vortexed for about 10 min. The mixture was centrifuged 
for 10 min at 4000 × g. The supernatant was transferred 
to the evaporation tube and evaporated to dryness in a 
thermostatically controlled water-bath maintained at 30 oC 
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under the stream of nitrogen for 20 min. The residue was 
dissolved in 3 mL of ethanol and transferred to quartz 
cells for analysis. Blank solution was prepared in a similar 
manner using drug-free human plasma.
Method validation
To ensure optimization of the method in light of the 
standardization rules, we developed this method along 
with the process of validation. The assay method was 
evaluated through determination of linearity, precision, 
specificity, limit of detection, limit of quantification, ac-
curacy and recovery, and the relative matrix effect was 
investigated by analyzing the different human plasma 
samples (Green, 1996; ICH, 1996).
Data analysis
All statistical calculations were performed using 
the Statistical Product and Service Solutions (SPSS) for 
Windows, version 10.0. Correlations were considered 
statistically significant if calculated P values were ≤0.05.
RESULTS AND DISCUSSION
Development of extraction procedure
To reduce the endogenous interfering substances, 
protein precipitation was performed. In the present meth-
od, the buffer solution (Na2CO3/NaHCO3) was used as the 
precipitant, and the ratio of the buffer solution to plasma 
was examined. The results showed that the best protein 
precipitation was achieved at a ratio of 1:4. Ether:hexane 
(1:1 v/v) was used as the solution for extraction after 
reconstitution of the residue, and the solution showed a 
good performance.
No internal standard was used in our study. An 
internal standard, although desirable, is not essential in 
the method as described. Because, external standards 
could be prepared along with the unknown samples and 
subsequently treated in parallel with the latter, an internal 
standard may not be required. In the present study, the 
external standard showed a satisfactory correlation and 
thus an internal standard was not required.
Optimization of parameters
The fluorescence spectra (excitation and emission) 
obtained for AD solutions extracted from spiked plasma 
reveals that the maximum λexc and λem show a band peak 
at 360 nm and 440 nm, respectively (Figure 2).
We evaluated the influence of the solvent on the 
relative intensity of fluorescence of AD. A solvent is an 
important parameter for developing an analytical method 
using fluorescence because the signal may undergo modi-
fications according to the solvent used. Changing solvent 
polarity can alter the absorption and emission spectra of 
AD. Solvents evaluated were ethanol, methanol, aceto-
nitrile, ether and water and the maximum fluorescence 
intensity was obtained in ethanol, and thus it was used 
throughout the study.
Linearity and calibration curve
Linearity of a calibration function is a critical 
analytical parameter (Green, 1996; ICH, 1996). The cor-
relation coefficient r2 has often been used to determine 
linearity. However, a correlation coefficient close to unity 
does not necessarily indicate a linear calibration function. 
Therefore, statistical tests for significant lack of fit to a 
linear model were used in these calibration experiments.
Solutions for the calibration curve were prepared 
by diluting the standard stock solutions (100 ppm) with 
ethanol in the range 0.09 - 13 ppm. These solutions were 
spiked in the plasma and then extracted from the plasma. 
Then, for each concentration, the emission fluorescence 
at 440 nm (excited at 360 nm) was measured 6 times in 
a random order. We found that the standard deviation of 
each measurement differs for each solution and therefore 
heteroscedasticity was present. In this case, the intercept 
A and slope B were estimated by weighted regression, 
which minimizes the value of Σijwi (Rij - ŘI)2 where Rij is 
the experimental fluorescence intensity value for each cij, 
ŘI is the fitted intensity, (Rij - ŘI) is the difference between 
experimental and fitted values or residuals. The weight is 
given by wi = σi – 2, where σi is the standard deviation of 
the fluorescence intensity at the concentration ci.
FIGURE 2 - Fluorescence spectra of AD solutions extracted 
from spiked human plasma (0.1, 1, 2, 4, 6, 8, 10 and 12.5 ppm).
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The linear calibration range of solutions extracted 
was 0.1 - 12.5 ppm in ethanol. The equation for the cali-
bration curve is I = A + B × C, where I is the fluorescence 
intensity (in arbitrary units) and C is the concentration of 
AD in ppm, A is the intercept and B is the slope. After a 
weighted least squares linear fit of the fluorescence emis-
sion data, the following values were obtained: A = 0.5418, 
B = 0.0524, and r2=0.9977. The number of measurements 
(n) was 6.
Limit of detection and limit of quantification
The limit of detection (LoD) and the limit of quanti-
tation (LoQ) were determined by an empirical method in 
which a series of solutions containing decreasing amounts 
of AD were analyzed. LoQ is the lowest amount of analyte 
that can be quantitatively determined with a suitable preci-
sion (RSD < 10%) and accuracy (80-120%). LoD is the 
lowest amount of analyte in a sample that can be detected 
but not necessarily quantitated as an exact value (RSD < 
10%) (ICH, 1996). LoQ and LoD values of the proposed 
method were 0.1 ppm and 0.07 ppm, respectively.
Accuracy and precision
The precision of the analytical method was deter-
mined by repeatability (within-day) and intermediate 
precision (between-day). Repeatability was evaluated by 
analyzing spiked blank human plasma samples 6 times per 
day at the same concentrations, which were plasma QC 
samples (1.5, 4.5, and 7.5 ppm) and during the same day. 
The intermediate precision was evaluated by assaying the 
same plasma samples in 6 times once daily for 6 days. The 
precision of the method was expressed as the relative stan-
dard deviation (RSD% =100 x standard deviation/mean) 
and the accuracy of method was expressed as the percent 
of mean deviation from known concentration [relative er-
ror (RE%)=(concentration found-known concentration) x 
100/known concentration]. The RSD% values for within-
day and between-day precision were ≤3.5%. The RE% for 
within-day and between-day accuracy of proposed method 
were ≤5.5%. Precision and accuracy studies in human 
plasma showed acceptable RSD% and RE% values. The 
results are shown in Table I.
Extraction recovery
The extraction recovery of AD from human plasma 
was determined at 1, 2, 6, 8, 10 and 12 ppm concentrations 
by comparing the data obtained by the direct injection of 
standard aqueous solutions with those obtained after the 
entire extraction procedure. The extraction recoveries 
of AD from plasma were between 90.0% and 99.7%, as 
shown in Table II.
TABLE I - Accuracy and precision of proposed method
Added (ppm)
Within-day Between-day
Found±SDa 
(ppm)
Accuracy 
bRE%
Precision 
cRSD %
Found±SDa 
(ppm)
Accuracy 
bRE%
Precision 
cRSD %
1.5 1.43±0.08 -4.6 3.5 1.52±0.07 1.0 3.0
4.5 4.68±0.06 -3.9 1.1 4.75±0.09 5.5 1.6
7.5 7.26±0.07 -3.6 0.8 7.24±0.09 -3.5 1.0
aSD: standard deviation of six replicate determinations; bRE: relative error; cRSD: relative standard deviation.
TABLE II- Extracted recovery of AD in spiked human plasma (n=6)
Added (ppm) Found (ppm) Recovery (%) Mean±SD RSD (%)
1.0 0.90 90.0
2.0 1.89 94.5
6.0 5.54 92.3 94.42±3.67 3.89
8.0 7.98 99.7
10.0 9.23 92.3
12.0 11.72 97.7
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TABLE III - Results of matrix effect for AD in plasma
Added (ppm)
1. Plasma 2. Plasma 3. Plasma
ME (RSD), % ME (RSD), % ME (RSD), %
1.5 98.3 (3.7) 97.9 (4.8) 94.8 (5.2)
4.5 96.0 (4.5) 98.3 (2.5) 97.9 (6.4)
7.5 97.8 (3.6) 96.9 (4.4) 95.6 (5.6)
ME: matrix effect, RSD: relative standard deviation
Stability of plasma samples
To determine of the stability of AD in the plasma, 
standard solutions of low (1.5 ppm), medium (5.0 ppm), 
and high (11.5 ppm) concentrations of the spiked calibra-
tion standards in the plasma were stored at room tem-
perature, in a refrigerator (4 oC) and in a deep freezer (-20 
oC) for 1 week. One set of spiked samples was assayed 
immediately and considered as the standard (100%). The 
results were evaluated, and these measurements were 
compared with those of standards and expressed as per-
centage deviation. AD was found to be stable for 24 h at 
room temperature and in the refrigerator and for at least 1 
week in the deep freezer.
For freeze-thaw stability studies, 1.5, 5.0, and 11.5 
ppm concentrations of AD were spiked into the plasma, 
and these samples were frozen at – 70 oC for 1 week and 
thawed 3 times a day. After these assays, the samples were 
extracted and analyzed. Our results showed that samples 
were stable for 24 h. In addition, we examined the stability 
of the analyte stock solution during 2 weeks in the same 
assay. Our results indicated that the stock solution was 
stable during 2 weeks at refrigerator temperature.
Matrix effect
For examined of the relative matrix effect, different 
human plasma samples were obtained from 3 hospitals in 
Erzurum, Turkey. Each blank sample was tested using the 
proposed extraction procedure for interference. The matrix 
effect was investigated using the following procedure: the 
fluorescence intensity of the standard QC samples was 
compared to the fluorescence intensity of AD in spiked 
QC sample with 3 different plasma samples. During the 
preparation of QC samples at same concentration level, 
each plasma sample was used only once. Matrix effect 
was calculated using this formula: I1/I2 x 100; where I1 
is the fluorescence intensity of the spiked QC samples in 
the plasma and I2 is the equivalent concentration of the 
standard samples in ethanol. Results of the matrix effect 
are summarized in Table III.
CONCLUSIONS
We developed and successfully validated the spec-
trofluorimetric method for the quantitative analysis of AD 
in human plasma. The proposed method is a rapid, simple, 
accurate, and reproducible method for the quantitative 
analysis of AD in human plasma. The proposed method is 
convenient for routine determination of AD in the plasma 
and quality control laboratories that require an economic 
and rapid method.
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